# Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers

> **NCT06443710** · PHASE1 · COMPLETED · sponsor: **Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Technetium [99mTc]-H7ND injection

## Key facts

- **NCT ID:** NCT06443710
- **Lead sponsor:** Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-14
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06443710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06443710, "Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06443710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*